CEO COMMENTS
Kristina Torfgård comments Q3 report 2024
“The important progress we made during the quarter, especially on our three most advanced projects mesdopetam, pirepemat and IRL757, has further strengthened our position, where the success of our projects bringing us closer to new and better treatments for people with Parkinson’s disease.”
LATEST REPORTS
The last patient has now completed the full treatment period in IRLAB’s Phase IIb study with pirepemat
Gothenburg, Sweden, January 14, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces that all patients enrolled in the Phase IIb study with the drug candidate pirepemat (REACT-PD) have completed their final follow-up visit. Topline data from the study are expected in the first quarter of 2025.
Read More >
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >FINANCIAL CALENDAR
NEXT
July 10, 2024
Interim Report January – June 2024